Iovance Biotherapeutics sharply raised its 2026 revenue outlook Tuesday as demand for its Amtagvi cell therapy and the accompanying Proleukin treatment continued to build, giving investors stronger evidence that the company’s commercial launch is moving beyond its early ramp. Iovance now expects full-year revenue of $410 million to $420 million, up from its previous $350 million to $370 million forecast. The $415 million midpoint is $55 million higher than before and would represent growth of roughly 58% from the $263.5 million Iovance generated in 2025.
Shares closed Tuesday at $14.45, up 31.48%, after reaching an intraday high of $15.30. The rally pushed Iovance to a new 52-week high and added roughly $1.6 billion to its market capitalization in a single session, reflecting how much investor expectations have shifted as Amtagvi sales have accelerated. The completed-session move was larger than the gains reported earlier Tuesday while trading was still underway.
The revised outlook is also modestly above the $410.6 million Wall Street consensus cited by FactSet in Barron’s. More important than the comparison with consensus, however, is what the new range requires from Iovance during the second half of the year: after generating $170.7 million of revenue through June, the company now needs approximately $239 million to $249 million during the final six months to reach guidance. That works out to an average of roughly $120 million to $125 million per quarter, about 20% to 25% above the record $99.3 million reported in the second quarter.
Commercial Scale Is Starting to Show in the Numbers
Second-quarter revenue had already signaled that Iovance’s launch was accelerating. Product revenue increased 66% from a year earlier to $99.3 million and rose 39% from the first quarter, while U.S. Amtagvi revenue reached approximately $91 million. Proleukin generated another roughly $9 million globally, and Iovance said it expects those sales to grow during the remainder of the year.
Iovance attributed the higher full-year outlook to continued patient demand and better visibility into its manufacturing schedule, an important consideration for an individualized cell therapy that requires a patient’s own tumor-derived immune cells to be collected, manufactured and returned for treatment. The company has expanded its network to approximately 100 authorized treatment centers and still expects at least 110 by the end of 2026, compared with more than 95 centers reported when second-quarter results were released in August.
Amtagvi received accelerated FDA approval in February 2024 for certain adults with unresectable or metastatic melanoma whose disease had already been treated with a PD-1 inhibitor and, when applicable, BRAF-targeted therapy. The approval made lifileucel the first FDA-approved cellular therapy for this form of melanoma, but its accelerated status means continued approval remains tied to confirmation of clinical benefit. Iovance’s ongoing Phase 3 TILVANCE-301 study is serving as the confirmatory trial while also evaluating lifileucel with pembrolizumab in previously untreated advanced melanoma.
Revenue Growth Is Improving the Financial Picture, but Iovance Is Still Burning Cash
The commercial expansion is beginning to improve more than revenue. Iovance reported a second-quarter gross margin of 56%, helped by higher Amtagvi volumes, manufacturing efficiencies and cost reductions. Its quarterly net loss narrowed to $47.3 million from $111.7 million a year earlier, while the net loss for the first six months of 2026 fell to $126.4 million from $227.8 million in the comparable 2025 period.
Cash consumption remains significant. Iovance used $132.9 million in operating activities during the first half, down from $171.1 million a year earlier, and held $303.7 million of cash, cash equivalents, short-term investments and restricted cash at the end of June. Management has said that balance, combined with its cost reductions and improving commercial performance, should support operations into the second half of 2028, although the company’s latest 10-Q cautions that Amtagvi and Proleukin sales may still be insufficient to produce positive operating cash flow over the coming 12 months.
That leaves Iovance in a different position from a year ago. The debate is becoming less about whether Amtagvi can generate meaningful commercial revenue and more about how quickly rising treatment volumes can translate into better manufacturing economics, narrower losses and eventually positive cash generation. Moving all clinical and commercial TIL manufacturing into Iovance’s internal facility was designed partly to improve gross margins, and the company says the site has capacity to supply therapies for more than 5,000 patients annually.
Wall Street forecasts now broadly reflect the second-half acceleration implied by management’s guidance. H.C. Wainwright raised its price target on Iovance to $20 following the update and increased its third- and fourth-quarter revenue estimates to $118.4 million and $125.9 million, respectively. Those two estimates total $244.3 million, almost exactly in the middle of the second-half revenue required by Iovance’s new annual outlook, although analyst forecasts remain estimates rather than company guidance.
Iovance is expected to report third-quarter results in early November. That report will provide the first direct test of the new outlook: revenue near the roughly $120 million quarterly pace implied by full-year guidance would show that the second-quarter acceleration is continuing, while gross margin and operating cash flow will indicate whether higher treatment volumes are producing the financial leverage needed to move the business closer to profitability.